Richard Law
Stock Analyst at Goldman Sachs
(2.72)
# 1,893
Out of 4,784 analysts
58
Total ratings
100%
Success rate
14.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Maintains: Sell | $6 → $4 | $3.43 | +16.79% | 2 | Mar 4, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $29 → $15 | $7.61 | +97.24% | 2 | Mar 3, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $42 → $36 | $19.81 | +81.74% | 2 | Mar 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $39.54 | +84.62% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $14.35 | +67.25% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $44.37 | +64.53% | 1 | Nov 21, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $25 → $31 | $14.53 | +113.35% | 2 | Sep 12, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $4.07 | +489.68% | 4 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $5.17 | +112.77% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $5.24 | +491.60% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $22.27 | +111.05% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $37.34 | +68.72% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $30.20 | +22.52% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $8.16 | +831.37% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $1.25 | +1,020.00% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.75 | +687.60% | 4 | May 8, 2023 |
Silence Therapeutics
Mar 4, 2025
Maintains: Sell
Price Target: $6 → $4
Current: $3.43
Upside: +16.79%
Rocket Pharmaceuticals
Mar 3, 2025
Maintains: Neutral
Price Target: $29 → $15
Current: $7.61
Upside: +97.24%
Celldex Therapeutics
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $36
Current: $19.81
Upside: +81.74%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $39.54
Upside: +84.62%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $14.35
Upside: +67.25%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $44.37
Upside: +64.53%
Viridian Therapeutics
Sep 12, 2024
Maintains: Buy
Price Target: $25 → $31
Current: $14.53
Upside: +113.35%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $4.07
Upside: +489.68%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $5.17
Upside: +112.77%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $5.24
Upside: +491.60%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $22.27
Upside: +111.05%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $37.34
Upside: +68.72%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $30.20
Upside: +22.52%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $8.16
Upside: +831.37%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $1.25
Upside: +1,020.00%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.75
Upside: +687.60%